ArticleThe American journal of pathology1989
A comparison between monoclonal antibody MT2 and immunoglobulin staining in the differential diagnosis of follicular lymphoid proliferations in routinely fixed wax-embedded biopsies.
Article in The American journal of pathology, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 13 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibody MT2 and anti-immunoglobulins were tested for their ability to discriminate between reactive lymphoid hyperplasia and follicular lymphoma (centroblastic/centrocytic; CB/CC) informalin-fixed and wax-embedded biopsies. The streptavidin biotin peroxidase complex method was used. In 46 of 49 cases of reactive follicular hyperplasia the follicle center cells were unstained by MT2 whereas the mantle zone B cells and interfollicular T cells were positive. In three reactive cases up to 30% of follicle center cells also were stained. In contrast, more than 50% of neoplastic follicle center cells were stained by MT2 in 27 of 62 cases of CB/CC, and light chain restriction was shown in 52 of 62 cases. MT2 staining and/or light chain restriction was seen in 57 of 62 cases. In 106 further cases of non-Hodgkin's lymphoma, MT2 was positive in 59 of 77 B cell lymphomas and 3 of 29 T cell lymphomas. Although not a B cell specific reagent, MT2 is useful in the differential diagnosis of reactive vs. neoplastic follicular lymphoid proliferations but is less sensitive than immunoglobulin stains.
Indexed as
Identifiers
2464283PMC1879565W2269165167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.